Actively Recruiting
Phase II Pilot Study of Oral Danazol for Treating Cytopenias in Adults with Compensated Cirrhosis
Led by University of Southern California · Updated on 2025-07-11
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of danazol in treating blood cell deficiencies called cytopenias in people with compensated Child-Pugh Class A or B liver cirrhosis. This phase II pilot study will include patients with or without specific telomere mutations or shortened telomeres. The study aims to enroll 10 patients and explore how danazol might help improve blood cell counts and overall liver health in this group. Participants will take danazol pills orally at a dose of 600 mg daily for 24 months. The study has a single treatment group where all patients receive danazol. The treatment period lasts two years, during which researchers will carefully monitor patients for any side effects or adverse events related to the medication. Throughout the study, participants will undergo regular evaluations including blood tests to track blood cell counts and telomere length, assessments of liver fibrosis and liver function, and monitoring for clinical events like liver decompensation or the need for transplant. Researchers will measure both hematologic response and the occurrence of significant adverse events over two years. The total participant involvement spans the full 24 months of treatment and monitoring.
CONDITIONS
Brief Title
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
Research Team
I
Ibrahim Syed, MBBS
C
Caitlin O'Neill, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here